6-K

SECURITIES AND EXCHANGE COMMISION
Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
The Securities Exchange Act of 1934

March 3, 2005

SCITEX CORPORATION LTD.
(Translation of registrant’s name into English)

3 Azrieli Center
Triangular Tower
Tel Aviv, 67023
Israel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.

Form 20-F x Form 40-F o

Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also furnishing the information to the Commission pursuant to Rule
12g3-2(b) under the Securities and Exchange Act of 1934.

Yes o No x



Attached to the Registrant’s Form 6-K, and incorporated by reference herein is the Registrant’s press release dated March 2, 2005, announcing Fourth Quarter and Full Year 2004 Results



SIGNATURE

Pursuant to the requirement of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SCITEX CORPORATION LTD.


BY: /S/ Yahel Shachar
——————————————
Yahel Shachar
Chief Financial Officer

March 3, 2005



NEWS

FOR IMMEDIATE RELEASE

Scitex Announces Fourth Quarter and Full Year 2004 Results

Scitex Vision concludes 2004 with 25% year-over-year growth to record annual revenues of $128 million
Scitex Vision achieves record quarterly revenues in the fourth quarter of more than $35 million
Scitex Corporation reports net income of $47.3 million in 2004 compared to a net income of $1.4 million in 2003

Tel Aviv, Israel – March 2, 2005. Scitex Corporation Ltd. (NASDAQ & TASE: SCIX) today announced financial results for the fourth quarter and full year ended December 31, 2004.

Management Comments

Ami Erel, Chairman of Scitex, commented: “I am delighted with the performance of Scitex during 2004. Our principal operating subsidiary, Scitex Vision, achieved an eighth consecutive quarter of revenue growth, with record quarterly revenues, operating profitability and positive cash flow. Scitex Vision took advantage of the renewed capital investment flow and increased ink demand with its wide product portfolio, loyal customers, and strong distribution and customer support infrastructure.”

Raanan Cohen, President and CEO of Scitex, commented: “2004 was an excellent year for Scitex. In 2004, Scitex made several significant strides commencing with the closing of the sale of SDP’s business to Kodak at the beginning of 2004 and continuing with distribution of nearly $120 million of the sale proceeds to our shareholders by way of a self tender offer and a cash distribution made in mid-year. Our primary subsidiary Scitex Vision achieved record revenues of over $128 million in 2004, representing 25% year-over-year revenue growth, and net income of $4.7 million (after a technology write-down of $2.3 million). Scitex Vision’s continued growth and record performance in 2004 substantiate its position as a leading player in its markets.”

Results of Operations

For fiscal year 2004, revenues were $128.2 million, an increase of 25% from $102.9 million in 2003. The operating loss in 2004 was $3.3 million compared to an operating loss of $12.3 million in 2003. The Company reported net income in 2004 of $47.3 million, primarily attributable to the capital gain derived from the sale of the operations of Scitex Digital Printing (SDP) to Eastman Kodak Company for $250 million (with an additional $12 million in cash retained by SDP after the sale), compared to net income of $1.4 million in 2003. Operating loss and net income for 2004 were impacted by a charge for impairment of technology of $5.6 million at Scitex Vision, $2.5 million of which was attributed to the minority shareholders of Scitex Vision under accounting principles; consequently, only $3.1 million of this impairment is reflected in Scitex Corporation’s net income and shareholders’ equity.



Geographically, Europe contributed 41% of 2004 revenues for Scitex Vision, followed by the Americas with 36% of revenues, and the Far East and rest of the world with 23% of revenues.

For the fourth quarter of 2004, revenues were $35.5 million, an increase of 25% from $28.5 million in the fourth quarter of 2003. The Company had an operating loss for the quarter of $4.6 million, compared to an operating loss of $3.5 million for the fourth quarter of 2003. The net loss reported by Scitex for the fourth quarter of 2004 amounted to $2.9 million compared to net income of $8 million in the fourth quarter of 2003. Operating loss and net loss for 2004 were impacted impairment of technology described above.

Balance Sheet and Cash Flow

On a consolidated basis, cash, cash equivalents and short-term investments at the end of 2004 were $142.6 million. This excludes restricted deposits of $13.0 million at Scitex Vision and of $10 million retained in a custodial account in connection with the sale of SDP’s operations ($5 million of which was released to Scitex in early January 2005), and represents a significant increase from $65.0 million at the end of 2003. The 2004 figure reflects the closing of the Kodak-SDP transaction, the approximate $28.1 million repurchase of shares by Scitex in the self tender offer completed in June 2004, and the approximate $89.8 million cash distribution made in the third quarter of 2004. Cash, cash equivalents and short-term investments at the end of 2004 at Scitex Corporation and its wholly-owned subsidiaries amounted to $132.4 million (excluding the above-described $10.0 million retained in a custodial account). Cash, cash equivalents and short-term investments at Scitex Vision at the end of 2004 amounted to $22.8 million (including the $13.0 million of restricted deposits), bringing the net debt of Scitex Vision to third parties, primarily bank borrowings, to approximately $23 million.

During the year, receivables increased to $33.6 million from $31.3 million, mainly due to increased revenue level and extended payments terms. Inventory in the year significantly increased to $36.7 million from $22.6 million due to increased business activities.

Scitex Vision

The fourth quarter of 2004, with record quarterly revenues of $35.5 million, highlights a remarkable year for Scitex Vision with continued revenue growth and strong operating and cash flow performance. Scitex Vision’s consistent quarter-over-quarter growth throughout the year was fueled by continued strong sales of its market leading super wide format product offerings, acceptance of the Scitex Vision TURBOjet (the industry’s most productive wide format digital press) and growth of ink sales.

During the year, Scitex Vision has substantially strengthened its manufacturing and customer support base to meet the growing demand and has considerably enhanced its technology base as a foundation for future products. It also completed ISO 9001/2000 certification at all of its global facilities and operations.

For the fiscal year 2004, Scitex Vision’s revenues were $128.2 million, compared to $102.9 million in 2003, reflecting a 25% increase. Operating income was $9 million in 2004, compared to an operating loss of $8.3 million in 2003. Scitex Vision had net income of $4.7 million in 2004, compared to a net loss of $13.6 million in 2003. Operating income and net income for 2004 were impacted by impairment of technology of $2.3 million compared to a $3.0 million technology write-down in 2003.

2



Scitex Vision reported record revenues for the eighth consecutive quarter and for the year. Revenues for the fourth quarter of 2004 were $35.5 million, an increase of 25% from $28.5 million in the corresponding quarter of 2003 and an increase of 9% from $32.7 million in the third quarter of 2004. Scitex Vision’s operating income in the fourth quarter of 2004 was $0.8 million, compared to an operating loss of $2.4 million in the fourth quarter of 2003, and operating income of $3.7 million in the third quarter of 2004. Scitex Vision’s net loss was $0.8 million in the fourth quarter of 2004, compared to a net loss of $1.7 million in the fourth quarter of 2003, and net income of $2.3 million in the third quarter of 2004. Operating income and net income for the fourth quarter of 2004 were impacted by impairment of technology described above.

Jemtex Ink Jet Printing Ltd.

Jemtex is a majority owned subsidiary of Scitex, based in Lod, Israel. During 2004, Jemtex continued developing and commenced commercialization of its digital printing engines for the ceramics and textile markets. During 2004, Scitex invested approximately $3 million in Jemtex in consideration for convertible debentures of Jemtex. Following this investment, Scitex holds approximately 74% of Jemtex’s issued share capital (84% assuming conversion of the debentures).

Conference Call

Scitex will be holding a conference call to discuss its fourth quarter 2004 and full year results on Thursday, March 3, 2005 at 9:00 a.m. EST (6:00 a.m. Pacific time, 2:00 p.m. GMT, 4:00 p.m. Israel time). All interested parties will have the opportunity to listen to a live simultaneous Webcast of the conference call by connecting online through www.scitex.com. A replay of the conference call will be available shortly after the call during the seven days following the conference call (until midnight March 10, 2004) at the following numbers:

US:
Intl:
Access code:
1 800 475-6701
1 320 365-3844
770949

Scitex Corporation Ltd.

Scitex Corporation shares trade on Nasdaq and The Tel Aviv Stock Exchange under the symbol “SCIX”. For more information, please visit our Web site at www.scitex.com.

3



Forward Looking Statements

Except for the historical information herein, the matters discussed in this news release include forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements that are based on various assumptions (some of which are beyond the Company’s control) may be identified by the use of forward-looking terminology, such as “may”, “can be”, “will”, “expects”, “anticipates”, “intends”, “believes”, “projects”, “potential”, “are optimistic”, “view” and similar words and phrases. Actual results could differ materially from those set forth in forward-looking statements due to a variety of factors, including, but not limited to, (1) risks in product and technology development, (2) market acceptance of new products and continuing product demand, (3) the impact of competitive products and pricing, (4) changes in domestic and foreign economic and market conditions, (5) timely development and release of new products by strategic suppliers, (6) the impact of the Company’s accounting policies, (7) risks relating to pursuing strategic alternatives, (8) uncertainty of outcome of shareholder litigation, and (9) the other risk factors detailed in the Company’s most recent annual report and other filings with the US Securities and Exchange Commission. Except as may be required by law, the Company does not undertake, and specifically disclaims, any obligation to publicly release the results of any revisions which may be made to any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such forward-looking statements.

Scitex and the Scitex logo are registered trademarks and registered service marks of Scitex Corporation Ltd. Scitex Vision and TURBOjet are registered trademarks and registered service marks of Scitex Vision Ltd.


Contact

Scitex Corporation Ltd.
Yahel Shachar
Chief Financial Officer
Tel:       +972 3 607-5855
Fax:       +972 3 607-5884
E-mail:  yahel.shachar@scitex.co.il

(Tables to Follow)

4



SCITEX CORPORATION LTD. (AN ISRAELI COMPANY) AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(U.S. Dollars in thousands, except per share data)

Quarter ended Dec. 31, Year ended Dec. 31,
2004 2003 2004 2003
(Unaudited)
(Unaudited)
(Audited)
(Audited)
Revenues                    
   Sales       21,252     16,954     78,418     60,653  
   Services & Supplies     14,242    11,586     49,767    42,227  




Total revenues     35,494    28,540     128,185    102,880  




Cost of revenues  
   Cost of sales     12,203    7,637     44,132    33,766  
   Cost of Services and Supplies     7,194    4,428     26,935    24,576  




Total cost of revenues     19,397    12,065     71,067    58,342  





Gross profit
     16,097    16,475     57,118    44,538  

Expenses
  
   Sales and marketing     5,063    8,300     19,990    20,192  
   General and administrative     4,510    3,927     16,614    15,147  
   Research and development, net     3,955    2,935     12,449    11,070  
   Amortization of other intangible assets     1,556    1,434     6,137    5,871  
   Impairment of other intangible assets     5,625    2,967     5,235    2,967  
    Restructuring charges        383        1,590  




Operating loss     (4,612 )  (3,471 )   (3,307 )  (12,299 )





    Financial Income (expense) - net
     (602 )  328     (276 )  (2,651 )
    Other income (expenses) - net     213    (68 )   470    787  





Loss before taxes on income
     (5,001 )  (3,211 )   (3,113 )  (14,163 )
    Taxes on income     1,220    (814 )   67    (2,402 )




      (3,781 )  (2,397 )   (3,046 )  (16,565 )

    Share in losses of associated companies
     (357 )  (1,521 )   (1,418 )  (5,637 )
    Minority interests in a subsidiary     1,239    440     71    3,546  




Net loss from continuing operations     (2,899 )  (3,478 )   (4,393 )  (18,656 )
Net Income from discontinued operations     0    11,494     51,646    20,043  




Net income (loss)     (2,899 )  8,016     47,253    1,387  





Earnings (loss) per share - basic & diluted
  
    Continuing operations   $ (0.08 ) $ (0.08 ) $ (0.11 ) $ (0.43 )
    Discontinued operations   $ 0.00   $ 0.27   $ 1.28   $ 0.46  




    $ (0.08 ) $ 0.19   $ 1.17   $ 0.02  




Weighted average number of shares used in  
computation of EPS (in thousands) - basic and diluted     38,066    43,018     40,336    43,018  







CONSOLIDATED BALANCE SHEETS
(U.S. Dollars in thousands)

December 31
2004
(Audited)

December 31
2003
(Audited)

Assets            

Current assets:
  
Cash and cash equivalents       85,892     56,761  
Short-term investments     56,693    8,235  
Restricted deposit     18,000    18,262  


Total cash and short-term investments     160,585    83,258  

Trade receivables
     33,585    31,279  
Other receivables     8,127    7,102  
Inventories     36,726    22,575  
Current Assets of discontinued operation        161,602  


Total current asssets     239,023    305,816  
  
Investments and other non-current assets     4,987    6,669  
  
Restricted deposit     5,000    0  
  
Property and equipment - net     9,147    9,204  
  
Goodwill and other intangible assets - net     15,996    23,499  
  
Non-Current Assets of discontinued operation        48,897  
  


      274,153    394,085  


Liabilities and Shareholders' Equity   
  
Current liabilities:  
Short term bank credit     30,755    49,251  
Current maturities of long -term loans     3,557    2,602  
Trade payables     21,877    14,505  
Accrued and other liabilities     40,200    47,466  
Current liabilities related to discontinued operation     2,193    31,935  


Total current liabilities     98,582    145,759  


Long-term liabilities:  
Loans from banks, net of current maturities     8,802    6,623  
Other     6,718    6,645  
Long-term liabilities related to discontinued operation        5,431  


Total long-term liabilities     15,520    18,699  
  
Long-term loans from related parties convertible  
    into shares of subsidiary     1,551    756  
  
Minority interest     4,226    4,173  
  
Shareholders' equity:  
Share capital     6,205    6,205  
Capital surplus     278,812    368,104  
Deferred stock compensation     (517 )
Accumulated other comprehensive loss     (327 )  (552 )
Accumulated deficit     (97,599 )  (144,852 )
Treasury shares, at cost     (32,300 )  (4,207 )


      154,274    224,698  


     
274,153
   
394,085
 




Scitex Vision Ltd.

US Dollar in Thousands

Three months ended
December 31
Year
December 31
2004 2003 2004 2003
Unaudited Unaudited Audited Audited
Revenues                    
   Sales    21,252    16,954    78,418    60,653  
   Services & Supplies    14,242    11,586    49,767    42,227  




Total Revenues    35,494    28,540    128,185    102,880  
  
Gross Profit    16,098    16,475    57,118    44,538  
  
Expenses:  
S,G&A    8,662    11,432    31,744    32,449  
Research and Development    3,365    2,935    10,281    11,070  
Amortization of other Intangible assets    968    1,147    3,776    4,725  
Impairment of other Intangible assets    2,333    2,967    2,333    2,967  
Restructuring Charges             394           1,602  
  
Operating (Loss) Income    770    (2,400 )  8,984    (8,275 )
  
Financial expenses    1,694    74    3449    2,907  
Other income    (26 )  (2 )  (212 )  (12 )
Taxes on income    (58 )  (812 )  1,054    2,402  
  




Net Income (Loss) for the year    (840 )  (1,660 )  4,693    (13,572 )